The purpose of this study is to find a cost effective cardiovascular (CV) surveillance of cancer survivors over long periods of time to prevent the risk of progression of heart failure (HF) and related morbidity and mortality. Mobile device-based artificial intelligence (AI)-electrocardiogram (ECG) can reliably detect cardiac dysfunction in lymphoma and sarcoma survivors and smart watch based surveillance for cardiotoxicity is feasible and reliable.
Protocol Amendment History
2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-07-01; most recent amendment 2025-10-13.
Status change: Not Yet Recruiting → Recruiting2025-10-13